Yidu Tech associate wins major clinical trial bid

Yidu Tech Inc. (Yidu Tech) has announced that its associate, Tianjin Happy Life Technology Co., Ltd., successfully secured a bid for a phase III clinical study project. The project, awarded by Shandong Yandu Biotechnology Co., Ltd., focuses on Recombinant Human Neurogenesis Factor (SMR001) Eye Drop. The total value of this project is approximately RMB55,817,597.00.

This successful bid highlights Yidu Tech's commitment to advancing AI-powered healthcare transformation. The company aims to make precision healthcare accessible through professional, efficient, precise, and inclusive AI medical products and solutions. Leveraging its proprietary YiduCore algorithm engine, the company has developed a "data-algorithm-scenario" flywheel ecosystem to drive efficient innovation and scalable AI applications across the healthcare value chain.

The core of Yidu Tech’s AI medical strategy is to enhance the quality and efficiency of medical evidence generation, optimizing the full lifecycle of research, diagnosis, and treatment. The company strives to improve healthcare services by empowering providers with decision-making tools, accelerating drug development, delivering affordable diagnostics, and supporting public health systems with scientific insights.